Table 3.
Effect of case:control status, treatment group, and their interaction (case:control status × treatment group) on biomarker concentrations. Cases represent participants with rapid FEV1 decline (≥ 40 mL/year), and controls are participants with stable FEV1 (− 20 mL/year to + 20 mL/year). Treatment group represents the effect of being in the virally suppressed vs untreated HIV groups on biomarker concentrations. All models incorporate sex as a covariate.
| F value | Pr (> F) | |
|---|---|---|
| Surfactant protein Da | ||
| Case:Control | 0.24 | 0.62 |
| Treatment group | 0.08 | 0.78 |
| Interaction | 0.00 | 0.96 |
| Club cell secretory protein | ||
| Case:Control | 0.69 | 0.41 |
| Treatment group | 0.35 | 0.56 |
| Interaction | 1.72 | 0.19 |
| Interleukin-6a | ||
| Case:Control | 0.47 | 0.49 |
| Treatment group | 2.54 | 0.11 |
| Interaction | 0.25 | 0.62 |
| C-reactive protein | ||
| Case:Control | 0.03 | 0.86 |
| Treatment group | 0.12 | 0.73 |
| Interaction | 1.34 | 0.25 |
| Fibrinogena | ||
| Case:Control | 2.02 | 0.16 |
| Treatment group | 0.009 | 0.92 |
| Interaction | 1.26 | 0.26 |
| D-Dimera | ||
| Case:Control | 0.47 | 0.49 |
| Treatment group | 6.49 | 0.01 |
| Interaction | 4.53 | 0.03 |
aThese models incorporate a random effect for masterplate based on AIC values.